



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

29 October 2018
EMA/628721/2018
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for medicinal products for human use (CHMP) Minutes of ORGAM¹ meeting on 10 September 2018

Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this minutes is considered commercially confidential or sensitive and therefore not disclosed.

Of note, this is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

¹ The CHMP ORGAM is a meeting to discuss CHMP organisational matters. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some ORGAM topics can be discussed at the CHMP Plenary. Please note that the ORGAM meeting is not taking place every month.



Table of contents

1.	Agenda and Minutes	3
1.1.	Welcome and declarations of interest of members, alternates and experts	3
1.2.	Adoption of agenda.....	3
1.3.	Adoption of the minutes	3
2.	Working Parties, Committees, SAGs and Drafting Groups	3
2.1.	General.....	3
2.2.	Biologicals	5
2.3.	Therapeutics.....	6
3.	Organisational, regulatory and methodological matters	9
3.1.	Regulatory Issues / new legislation	9
4.	Any Other Business	9
4.1.	Telematics strategy 2020-2025: Concept Paper	9
5.	List of participants	9

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda

CHMP ORGAM agenda for 10 September 2018 meeting was adopted.

1.3. Adoption of the minutes

CHMP Orgam Minutes of September 2018 meeting will be adopted at the September 2018 CHMP plenary.

2. Working Parties, Committees, SAGs and Drafting Groups

2.1. General

2.1.1. Safety Working Party (SWP)

Chair: Jan Willem Van der Laan

No items

2.1.2. Quality Working Party (QWP)

Chair: Keith Pugh/Blanka Hirschlerova

CMDh question to QWP on latex rubber stoppers (EMA/585665/2018)

Action: For adoption

The CMDh question to QWP on latex rubber stoppers was presented. The CHMP adopted the questions to be addressed by QWP.

2.1.3. Scientific Advice Working Party (SAWP)

Chair: Robert Hemmings

No items

2.1.4. European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP)

Co-chair: Kaisa Immonen

No items

2.1.5. European Medicines Agency Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP)

Co-chair: Gonzalo Calvo

No items

2.1.6. Geriatric Expert Group (GEG)

Chair: Katarina Vučić

No items

2.1.7. Committees

No items

2.1.8. International Council on Harmonisation (ICH)

ICH S11 technical document on Nonclinical Safety Testing in Support of Development of Paediatric Medicines – Step2b

Action: For adoption for 6 month public consultation

The CHMP adopted the document for 6 month public consultation.

CeSHarP: Call for expression of interest of one expert

Action: For information

The ICH documents were presented. The CHMP noted that the call for Clinical electronic Structured Harmonized Protocol (CeSHarP) for EU experts in the clinical trials field/ protocol design was made. CeSHarP aims to specify a comprehensive clinical protocol organization and flexible content components; lay down the business requirements to drive development of a technical specification enabling electronic exchange of clinical protocol information and promote consistency in the protocol content and enabling cross-study protocol analysis as well as the development of protocol review tools or templates. Informal Working Group started in August 2017. The work of the CeSHarP group will start in June next year, however the group should be formed now. It was agreed to come back to this during the September Plenary.

2.1.9. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J3RsWG)

Chair: Ellen-Margrethe Vestergaard, CoChair: Susanne Brendler-Schwaab

No items

2.1.10. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

Chair: Nienke Rodenhuis

No items

2.1.11. Joint CVMP-CHMP antimicrobial advice ad hoc expert group (AMEG)

Chair: Gérard Moulin

No items

2.1.12. Modelling and Simulation Working Party (MSWP)

Chair: Kristin Karlsson/Flora Musuamba Tshinanu

No items

2.2. Biologicals

2.2.1. Biosimilar Medicinal Product Working Party (BMWP)

Chair: Elena Wolff-Holz/Niklas Ekman

No items

2.2.2. Biologicals Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Final minutes from June face-to-face meeting held 18-20 June 2018
(EMA/CHMP/BWP/417987/2018)

Action: For information

The CHMP noted the final minutes.

Draft agenda for BWP face-to-face meeting to be held 8-10 October 2018
(EMA/CHMP/BWP/566496/2018)

Action: For information

The CHMP noted the draft agenda.

Nomination of alternate member to BWP:

Pavel Simek from the Czech Republic (from 1 September 2018, replacing Dagmar Pospisilova)

Action: For adoption

The CHMP appointed Pavel Simek from the Czech Republic as alternate member to BWP.

2.2.3. Vaccines Working Party (VWP)

Chair: Mair Powell/Svein Rune Andersen

Nomination of additional assessor to VWP:

Karen Goetz from Germany (PEI)

Action: For adoption

The CHMP nominated Karen Goetz from Germany (PEI) as additional assessor to VWP.

2.2.4. Blood Products Working Party (BPWP)

Chair: Jacqueline Kerr

No items

2.2.5. Pharmacogenomics Working Party (PGWP)

Chair: Krishna Prasad/Markus Paulmichl

No items

2.3. Therapeutics

2.3.1. Cardiovascular Working Party (CVSWP)

Chair: Kristina Dunder/Alar Irs

No items

2.3.2. Central Nervous System Working Party (CNSWP)

Chair: Karl Broich/André Elferink

No items

2.3.3. Infectious Diseases Working Party (IDWP)

Chair: Maria Jesus Fernandez Cortizo

No items

2.3.4. Oncology Working Party

Chair: Pierre Demolis/Paolo Foggi

No items

2.3.5. Pharmacokinetics Working Party (PKWP)

Chair: Jan Welink/Henrike Potthast

Nomination of additional assessor to PKWP:

Paula Coppola (UK)

- Paula Coppola's CV
- Nomination letter

Action: For adoption

The CHMP nominated Paula Coppola (UK) as additional assessor to PKWP.

Nomination of additional assessor to PKWP:

Petr Vrbata (CZ) - replacing Marina Feřtek

- Petr Vrbata's CV
- Nomination letter

Action: For adoption

The CHMP nominated Petr Vrbata (CZ), replacing Marina Feřtek, as additional assessor to PKWP.

2.3.6. **Biostatistics Working Party (BSWP)**

Chair: Anja Schiel/Jörg Zinserling

No items

2.3.7. **Rheumatology/Immunology Working Party (RIWP)**

Chair: Jan Mueller-Berghaus/Romaldas Mačiulaitis

Response from RIWP and PKWP to CMDh questions on Classification as Narrow Therapeutic Index (NTI) drug and advice on requirements for bioequivalence studies – colchicine (EMA/CHMP/494830/2018)

Action: For adoption

The CHMP noted the response, however it was agreed to come back to this during the September Plenary so that members will have sufficient time to familiarize themselves with the document.

2.3.8. **Scientific Advisory Groups (SAGs)**

No items

2.3.9. **Drafting Groups (DGs)**

2.3.9.1. **Gastroenterology Drafting Group (GDG)**

Chair: Mark Ainsworth

No items

2.3.9.2. Respiratory Drafting Group (RDG)

Chair: Karolina Törneke

No items

2.3.9.3. Radiopharmaceutical Drafting Group (RadDG)

Chair: Anabel Cortes

No items

2.3.9.4. Excipients Drafting Group

Chair: Dominique Masset

Information for the package leaflet regarding dextrans used as excipients in medicinal products for human use (EMA/CHMP/187129/2016)

Action: For adoption for 6-month public consultation

The CHMP noted the document. In case no comments are sent, the document will be adopted during the September plenary.

Information for the package leaflet regarding proline used as an excipient in medicinal products for human use (EMA/CHMP/108086/2016)

Action: For adoption for 6-month public consultation

The CHMP noted the document. In case no comments are sent, the document will be adopted during the September plenary.

Information for the package leaflet regarding lactose used as an excipient in medicinal products for human use (EMA/CHMP/186428/2016)

Action: For adoption for 6-month public consultation

The CHMP noted the document. In case no comments are sent, the document will be adopted during the September plenary.

Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use (EMA/CHMP/190743/2016)

Action: For adoption for 6-month public consultation

The CHMP noted the document. In case no comments are sent, the document will be adopted during the September plenary.

2.3.10. Additional agenda points

2.3.10.1. Innovation Task Force

No items

2.3.10.2. Guideline Consistency Group (GCG)

Chair: Aranzazu Sancho-Lopez

No items

2.3.10.3. IPRF Nano Working Group

Chair: Harald Enzmann

No items

3. Organisational, regulatory and methodological matters

3.1. Regulatory Issues / new legislation

3.1.1. EMA Implementation plan of the new medical device and in vitro diagnostic regulation

Action: For discussion

Follow-up from July Plenary was presented. Sponsors were invited for the scientific opinion on the definitions of Pharmacological, Immunological, Metabolic and Medical diagnosis, which are being revised by EC Borderline and classification group. The CHMP noted the volunteers from CHMP. A request from European Commission is expected by Q4 2018. The proposal is for CHMP / CAT scientific opinion through 60 day procedure. Further discussions will be held with volunteers in the margins of September CHMP Plenary.

4. Any Other Business

4.1. Telematics strategy 2020-2025: Concept Paper

Action: For discussion

The CHMP noted the call for volunteers for telematics strategy as presented during the July CHMP Plenary. Further discussions and volunteer nominations are to be held during the CHMP September Plenary.

5. List of participants

CHMP Chair:

Tomas Salmonson

CHMP members:

Emilia Mavrokordatou

Ewa Balkowiec Iskra

Greg Markey

Jan Mueller-Berghaus
Jayne Crowe
Johann Lodewijk Hillege
Katarina Vučić
Outi Mäki-Ikola
Svein Rune Andersen

CHMP alternate members:

Christophe Focke
Dana Gabriela Marin
Martina Weise
Milena Stain
Nithyanandan Nagercoil

Experts:

Dominique Masset
Irene Diaz Ortiz
Theis Moeslund Jensen

A representative from the European Commission attended the meeting.

The meeting was run with support from the relevant EMA staff.